2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Acute Pain D059787 3 associated lipids
Acute Lung Injury D055371 33 associated lipids
Fetal Nutrition Disorders D048070 1 associated lipids
Ganglion Cysts D045888 1 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Head Injuries, Closed D016489 5 associated lipids
Weight Gain D015430 101 associated lipids
Myocardial Reperfusion Injury D015428 20 associated lipids
Reperfusion Injury D015427 65 associated lipids
Stomach Ulcer D013276 75 associated lipids
Starvation D013217 47 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Pain D010146 64 associated lipids
Obesity D009765 29 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Neuralgia D009437 28 associated lipids
Nervous System Diseases D009422 37 associated lipids
Nerve Degeneration D009410 53 associated lipids
Morphine Dependence D009021 9 associated lipids
Memory Disorders D008569 33 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Inflammation D007249 119 associated lipids
Hypothermia D007035 19 associated lipids
Hypotension D007022 41 associated lipids
Hyperkinesis D006948 11 associated lipids
Hyperinsulinism D006946 27 associated lipids
Hyperalgesia D006930 42 associated lipids
Hepatic Encephalopathy D006501 9 associated lipids
Glioma D005910 112 associated lipids
Fragile X Syndrome D005600 5 associated lipids
Fatty Liver, Alcoholic D005235 11 associated lipids
Epilepsy D004827 35 associated lipids
Encephalitis D004660 15 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Colitis D003092 69 associated lipids
Brain Ischemia D002545 89 associated lipids
Catalepsy D002375 30 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Brain Edema D001929 20 associated lipids
Brain Concussion D001924 5 associated lipids
Body Weight D001835 333 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
DeVuono MV et al. Conditioned gaping produced by high dose Δ-tetrahydracannabinol: Dysregulation of the hypothalamic endocannabinoid system. 2018 Neuropharmacology pmid:30195587
Ratano P et al. Pharmacological inhibition of 2-arachidonoilglycerol hydrolysis enhances memory consolidation in rats through CB2 receptor activation and mTOR signaling modulation. 2018 Neuropharmacology pmid:29842858
Shonesy BC et al. The initiation of synaptic 2-AG mobilization requires both an increased supply of diacylglycerol precursor and increased postsynaptic calcium. 2015 Neuropharmacology pmid:25484252
Atwood BK et al. CBâ‚‚ cannabinoid receptors inhibit synaptic transmission when expressed in cultured autaptic neurons. 2012 Neuropharmacology pmid:22579668
Pasquarelli N et al. Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS. 2017 Neuropharmacology pmid:28373073
Kortleven C et al. Neurotensin inhibits glutamate-mediated synaptic inputs onto ventral tegmental area dopamine neurons through the release of the endocannabinoid 2-AG. 2012 Neuropharmacology pmid:22884466
Nader J et al. Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors. 2014 Neuropharmacology pmid:24709540
Hashimotodani Y et al. Pharmacological evidence for the involvement of diacylglycerol lipase in depolarization-induced endocanabinoid release. 2008 Neuropharmacology pmid:17655882
Mátyás F et al. Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. 2008 Neuropharmacology pmid:17655884
Pasquarelli N et al. Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue. 2015 Neuropharmacology pmid:25497453
Moreira FA et al. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. 2008 Neuropharmacology pmid:17709120
Chiu CQ and Castillo PE Input-specific plasticity at excitatory synapses mediated by endocannabinoids in the dentate gyrus. 2008 Neuropharmacology pmid:17706254
Morena M et al. Emotional arousal state influences the ability of amygdalar endocannabinoid signaling to modulate anxiety. 2016 Neuropharmacology pmid:27553121
Citraro R et al. Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy. 2013 Neuropharmacology pmid:23206503
Rubio M et al. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats. 2008 Neuropharmacology pmid:18371990
Al-Hayani A et al. The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. 2001 Neuropharmacology pmid:11747904
Suplita RL et al. Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. 2006 Neuropharmacology pmid:16316669
Desroches J et al. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors. 2014 Neuropharmacology pmid:24148808
Morgan NH et al. Functional CB2 type cannabinoid receptors at CNS synapses. 2009 Neuropharmacology pmid:19616018
Sticht MA et al. Endocannabinoid regulation of nausea is mediated by 2-arachidonoylglycerol (2-AG) in the rat visceral insular cortex. 2016 Neuropharmacology pmid:26541329
Placzek EA et al. Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown. 2008 Neuropharmacology pmid:18760289
Best AR and Regehr WG Identification of the synthetic pathway producing the endocannabinoid that mediates the bulk of retrograde signaling in the brain. 2010 Neuron pmid:20159441
Oleson EB et al. Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum. 2012 Neuron pmid:22284189
Safo PK and Regehr WG Endocannabinoids control the induction of cerebellar LTD. 2005 Neuron pmid:16301180
Gantz SC and Bean BP Cell-Autonomous Excitation of Midbrain Dopamine Neurons by Endocannabinoid-Dependent Lipid Signaling. 2017 Neuron pmid:28262417
Duan Y et al. Inhibition of [3H]batrachotoxinin A-20alpha-benzoate binding to sodium channels and sodium channel function by endocannabinoids. 2008 Neurochem. Int. pmid:17888543
Bardell TK and Barker EL Activation of TRPC6 channels promotes endocannabinoid biosynthesis in neuronal CAD cells. 2010 Neurochem. Int. pmid:20466028
Sang N et al. Anandamide potentiation of miniature spontaneous excitatory synaptic transmission is mediated via IP3 pathway. 2010 Neurochem. Int. pmid:20064571
Arevalo-Martin A et al. The endocannabinoid 2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal cord injury. 2010 Neurobiol. Dis. pmid:20156559
Piomelli D et al. Endogenous cannabinoid signaling. 1998 Neurobiol. Dis. pmid:9974178
Panikashvili D et al. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. 2006 Neurobiol. Dis. pmid:16364651
Vázquez C et al. Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: In vivo studies. 2015 Neurobiol. Dis. pmid:25917763
Avraham Y et al. Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. 2006 Neurobiol. Dis. pmid:16102970
Garcia-Ovejero D et al. The endocannabinoid system is modulated in response to spinal cord injury in rats. 2009 Neurobiol. Dis. pmid:18930143
Melis M et al. Protective activation of the endocannabinoid system during ischemia in dopamine neurons. 2006 Neurobiol. Dis. pmid:16762556
Cabranes A et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. 2005 Neurobiol. Dis. pmid:16242629
Fernández-Suárez D et al. Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. 2014 Neurobiol. Aging pmid:24973119
Feliszek M et al. Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184. 2016 Naunyn Schmiedebergs Arch. Pharmacol. pmid:26984820
Schulte K et al. Cannabinoid CB1 receptor activation, pharmacological blockade, or genetic ablation affects the function of the muscarinic auto- and heteroreceptor. 2012 Naunyn Schmiedebergs Arch. Pharmacol. pmid:22215206
Ameri A and Simmet T Effects of 2-arachidonylglycerol, an endogenous cannabinoid, on neuronal activity in rat hippocampal slices. 2000 Naunyn Schmiedebergs Arch. Pharmacol. pmid:10731038
Ilayan E et al. Do cannabinoids exhibit a tyramine-like effect? 2013 Naunyn Schmiedebergs Arch. Pharmacol. pmid:23900610
Jergas B et al. O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus. 2014 Naunyn Schmiedebergs Arch. Pharmacol. pmid:24853577
Hohmann AG et al. An endocannabinoid mechanism for stress-induced analgesia. 2005 Nature pmid:15973410
Di Marzo V et al. Trick or treat from food endocannabinoids? 1998 Nature pmid:9872309
Panikashvili D et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. 2001 Nature pmid:11586361
Di Marzo V et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. 2001 Nature pmid:11298451
Wilson RI and Nicoll RA Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. 2001 Nature pmid:11279497
Stella N et al. A second endogenous cannabinoid that modulates long-term potentiation. 1997 Nature pmid:9285589
Giuffrida A et al. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. 1999 Nat. Neurosci. pmid:10204543
Marrs WR et al. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. 2010 Nat. Neurosci. pmid:20657592